Trial reportBone marrow transplantation2010
The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
Trial report in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases.Medical oncology (Northwood, London, England) · 2014Trial
- Haploidentical Stem Cell Transplantation With Dual Source of Cells and Post-Transplant Cyclophosphamide.Cancer medicine · 2025Article
- Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.Bone marrow transplantation · 2024Article
- Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation.Frontiers in immunology · 2022Article
- [Comparison of the clinical outcomes of haploidentical and matched-sibling donor stem cell transplantation for T cell acute lymphoblastic leukemia in complete remission].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study.Frontiers in oncology · 2021Article
- Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience.Annals of transplantation · 2019Article
- Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant.Journal of hematology & oncology · 2017Article
- Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update.Bone marrow transplantation · 2016Article
- G-CSF-primed BM for allogeneic SCT: revisited.Bone marrow transplantation · 2015Review
- Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.World journal of transplantation · 2013Review
- Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.Frontiers of medicine · 2013Review
- A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia.Bone marrow transplantation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate the efficacy and feasibility of unmanipulated haploidentical PBSCT for the treatment of acute leukemia (AL). This study compares the clinical outcomes of high-risk AL patients who received PBSCs harvested from family members sharing at least one common haplotype to outcomes of high-risk AL patients who received a mixture of G-CSF-primed BM (G-BM) and peripheral blood (G-PB) harvests. The results show that PBSCT achieved inferior cumulative myeloid engraftment at 30 days after transplant (89.9 + or - 10.1% vs 100%; P=0.04), with lower cumulative incidence of grade II-IV acute GVHD (aGVHD) (37.1 + or - 16.5% vs 63.2+/-6%; P=0.058) compared with G-BM/G-PB transplant. However, both transplant protocols had similar rates of 2-year relapse (29.6 + or - 17.1% vs 34.0 + or - 5.7%; P=0.954), and PBSCT produced a higher incidence of 2-year non-leukemic mortality (62.5 + or - 14.8% vs 35.1 + or - 5.1%; P=0.014), as well as lower rates of overall (26.8 + or - 12.3% vs 43.2 + or - 5.0%; P=0.052) and disease-free survival (26.8 + or - 12.3% vs 42.4 + or - 5.0%; P=0.071) compared with G-BM/G-PB transplant. These results suggest that haploidentical HSCT is an option for patients with AL who urgently need a graft and do not have matched sibling donors. PBSCT is potentially inferior to G-BM/G-PB transplant, and improvements should be made before PBSCT becomes a routine in unmanipulated mismatched/haploidentical transplant settings.
Indexed as
Identifiers
19898505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.